ArticleInternational journal of clinical and experimental pathology2015
Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcoma.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Circulating MicroRNAs as Novel Potential Diagnostic Biomarkers for Osteosarcoma: A Systematic Review.Biomolecules · 2021Pooled it
- Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis.Frontiers in genetics · 2020Pooled it
- Regulation and function of microRNA-152 in various types of cancers: its upstream regulators and downstream targets.Clinical and experimental medicine · 2025Review
- A comprehensive overview of liquid biopsy applications in pediatric solid tumors.NPJ precision oncology · 2024Review
- Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations.International journal of molecular sciences · 2022Review
- Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis.Journal of bone oncology · 2020Review
- Differential expression of AURKA/PLK4 in quiescence and senescence of osteosarcoma U2OS cells.Cell cycle (Georgetown, Tex.) · 2020Article
- Advances in the role of miRNAs in the occurrence and development of osteosarcoma.Open medicine (Warsaw, Poland) · 2020Article
- Curcumol inhibits the proliferation and metastasis of melanoma via the miR-152-3p/PI3K/AKT and ERK/NF-κB signaling pathways.Journal of Cancer · 2020Article
- MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.Cancer cell international · 2020Review
- Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.Journal of clinical medicine · 2019Review
- Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.Cancers · 2019Review
- Screening of disorders associated with osteosarcoma by integrated network analysis.Bioscience reports · 2019Article
- Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.Investigational new drugs · 2018Review
- MicroRNA-152 Suppresses Human Osteosarcoma Cell Proliferation and Invasion by Targeting E2F Transcription Factor 3.Oncology research · 2018Article
- Serum miR-542-3p as a prognostic biomarker in osteosarcoma.Cancer biomarkers : section A of Disease markers · 2018Article
- miR-30a suppresses osteosarcoma proliferation and metastasis by downregulating MEF2D expression.OncoTargets and therapy · 2018Article
- Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.Oncotarget · 2017Review
- MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis.Oncotarget · 2017Article
- Evaluating the prognostic value of miR-148/152 family in cancers: based on a systemic review of observational studies.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Potential values of microRNA152 (miR-152) as a serum diagnostic and prognostic biomarker have not been determined in human osteosarcoma. By detecting the expression of miR-152 among 80 osteosarcoma patients, 20 periostitis patients and 20 healthy individuals using qRT-PCR, we aimed to explore the clinical significance of miR-152 in osteosarcoma patients. The expression of miR-152 was significantly decreased in patients with osteosarcoma compared to patients with periostitis (P<0.01) and healthy controls (P<0.01). The relationship between clinicopathologic characteristics and miR-152 was analyzed by chi-square test. The outcome indicated that miR-152 might be linked with the development of osteosarcoma. Moreover, the receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of miR-152. The result demonstrated that miR-152 might be a promising diagnostic marker of osteosarcoma with an AUC of 0.956, combing with 92.5% specificity and 96.2% sensitivity. The relationship between miR-152 and overall survival of osteosarcoma patients was analyzed by Kaplan-Meier curve and log rank test. As a result, the survival time of patients with low miR-152 expression was significantly shorter than those with high miR-152 expression (P<0.001). Then Cox regression analysis was used to estimate the prognostic value of miR-152 in osteosarcoma. The outcomes showed that low miR-152 expression (P=0.004) might be a potential independent prognostic marker for osteosarcoma patients. These findings suggested that down-regulation of miR-152 could be considered as a predictor for diagnosis and prognosis of osteosarcoma patients.
Indexed as
Identifiers
26464682PMC4583914W2464426059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.